Previous 10 | Next 10 |
Montrouge, France, September 9, 2020 DBV Technologies Announces Leadership Changes DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Ramzi Benamar, Chief Financial Officer, and Kev...
Montrouge, France, September 2, 2020 DBV Technologies to Participate in Multiple September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participatio...
Aimmune Therapeutics (NASDAQ: AIMT ) +171% on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010...
Investors had high expectations for Aimmune Therapeutics (NASDAQ: AIMT) at the beginning of the year. Its stock performed well in 2019 -- with its shares surging by more than 30% -- and the biotech was on the verge of getting approval from the U.S. Food and Drug Administration (FDA) for Palf...
Aerpio Pharmaceuticals (NASDAQ: ARPO ) +61% on announcing a second clinical trial with funding from MTEC. More news on: Aerpio Pharmaceuticals, Inc., Whiting Petroleum Corporation, Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Gainers: Alterity Therapeutics (NASDAQ: ATHE ) +210% . More news on: Alterity Therapeutics Limited, SilverSun Technologies, Inc., Universal Security Instruments, Inc., Stocks on the move, , Read more ...
DBV Technologies (NASDAQ: DBVT ) slumps 30% premarket in reaction to its announcement that it received a Complete Response Letter (CRL) from the FDA regarding its BLA for investigational Viaskin Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat pean...
Montrouge, France, August 4, 2020 DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...